JP2019507724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507724A5 JP2019507724A5 JP2018535304A JP2018535304A JP2019507724A5 JP 2019507724 A5 JP2019507724 A5 JP 2019507724A5 JP 2018535304 A JP2018535304 A JP 2018535304A JP 2018535304 A JP2018535304 A JP 2018535304A JP 2019507724 A5 JP2019507724 A5 JP 2019507724A5
- Authority
- JP
- Japan
- Prior art keywords
- dysplasia
- prodrug
- syndrome
- pharmaceutically acceptable
- cnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031431A JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150624 | 2016-01-08 | ||
| EP16150624.1 | 2016-01-08 | ||
| EP16179286.6 | 2016-07-13 | ||
| EP16179286 | 2016-07-13 | ||
| EP16191458.5 | 2016-09-29 | ||
| EP16191458 | 2016-09-29 | ||
| PCT/EP2017/050201 WO2017118693A1 (en) | 2016-01-08 | 2017-01-05 | Cnp prodrugs with large carrier moieties |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031431A Division JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A Division JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507724A JP2019507724A (ja) | 2019-03-22 |
| JP2019507724A5 true JP2019507724A5 (https=) | 2019-12-19 |
| JP7051686B2 JP7051686B2 (ja) | 2022-04-11 |
Family
ID=57838356
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2021031431A Active JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031431A Active JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10835578B2 (https=) |
| EP (1) | EP3400020A1 (https=) |
| JP (4) | JP7051686B2 (https=) |
| AU (2) | AU2017205268B2 (https=) |
| CA (1) | CA3007976C (https=) |
| MX (1) | MX2018008061A (https=) |
| WO (1) | WO2017118693A1 (https=) |
| ZA (1) | ZA201804414B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| IL297375B2 (en) * | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| HUE062117T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| EP4011396A1 (en) | 2017-03-10 | 2022-06-15 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
| WO2019185705A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
| AU2019340472A1 (en) | 2018-09-12 | 2021-04-01 | Quiapeg Pharmaceuticals Ab | Releasable GLP-1 conjugates |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| MX2022014082A (es) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
| US20230241164A1 (en) * | 2020-06-12 | 2023-08-03 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer |
| CA3236278A1 (en) * | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
| IL316466A (en) * | 2022-05-23 | 2024-12-01 | Ascendis Pharma Growth Disorders As | Liquid pharmaceutical formulations of cnp compounds |
| EP4612167A1 (en) | 2022-11-02 | 2025-09-10 | Novo Nordisk A/S | Cnp compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| AU2003297583B2 (en) | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| MXPA06010782A (es) | 2004-03-23 | 2007-03-28 | Complex Biosystems Gmbh | Ligador de profarmaco. |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| JP2010502231A (ja) | 2006-09-08 | 2010-01-28 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド |
| JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| TWI409081B (zh) | 2006-11-09 | 2013-09-21 | Alcon Res Ltd | 用於藥物輸送之水不溶性聚合物基質 |
| WO2008131179A1 (en) * | 2007-04-20 | 2008-10-30 | Shell Oil Company | In situ heat treatment from multiple layers of a tar sands formation |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| TW201004648A (en) | 2008-05-23 | 2010-02-01 | Enzon Pharmaceuticals Inc | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| WO2010033216A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| ES2608457T3 (es) | 2009-05-20 | 2017-04-11 | Biomarin Pharmaceutical Inc. | Variantes de péptido natriurético de tipo C |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
| EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| MX349950B (es) | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| HK1198913A1 (en) | 2011-08-12 | 2015-06-19 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| JPWO2013161895A1 (ja) | 2012-04-25 | 2015-12-24 | 第一三共株式会社 | 骨修復促進剤 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| KR20160118264A (ko) | 2014-02-27 | 2016-10-11 | 다이이찌 산쿄 가부시키가이샤 | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 |
| CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| EP3242689A1 (en) | 2015-01-09 | 2017-11-15 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
| PL3386531T3 (pl) | 2015-12-08 | 2022-02-28 | Biomarin Pharmaceutical Inc. | Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów |
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| MX2018008061A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| HUE062117T2 (hu) * | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
-
2017
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en not_active Ceased
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP7692454B2/ja active Active
-
2024
- 2024-01-08 US US18/407,324 patent/US20240316153A1/en not_active Abandoned
- 2024-12-19 US US18/986,709 patent/US20250127859A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507724A5 (https=) | ||
| JP2019510735A5 (https=) | ||
| JP2019507725A5 (https=) | ||
| JP7692454B2 (ja) | 大型のキャリアー部分を有するｃｎｐプロドラッグ | |
| JP7714087B2 (ja) | 増加したｎｅｐ安定性を有する徐放ｃｎｐ作動薬 | |
| JP7816947B2 (ja) | 環部分にキャリア結合を有するｃｎｐプロドラッグ | |
| KR102599552B1 (ko) | Cnp 프로드럭 | |
| EP3400065B1 (en) | Controlled-release cnp agonists with reduced side-effects | |
| JP6685046B2 (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| CN103596584A (zh) | 多取代的胰岛素 | |
| CA3064320A1 (en) | Mic-1 compounds and uses thereof | |
| CN105148289B (zh) | 一种两亲性寡聚多肽药物结合物 | |
| US12415834B2 (en) | GhR-binding peptide and composition comprising same | |
| CN120641434A (zh) | 人类运铁蛋白受体结合肽 | |
| HK1246666A1 (zh) | Cnp前药 | |
| HK1246666B (en) | Cnp prodrugs | |
| HK1262548A1 (en) | Cnp prodrugs with carrier attachment at the ring moiety | |
| HK1262548B (en) | Cnp prodrugs with carrier attachment at the ring moiety |